...
首页> 外文期刊>Journal of Molecular and Cellular Cardiology >High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets
【24h】

High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets

机译:用于人IPSC衍生的心肌细胞增殖的高含量表型测定鉴定L型钙通道作为靶标

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Over 5 million people in the United States suffer from heart failure, due to the limited ability to regenerate functional cardiac tissue. One potential therapeutic strategy is to enhance proliferation of resident cardiomyocytes. However, phenotypic screening for therapeutic agents is challenged by the limited ability of conventional markers to discriminate between cardiomyocyte proliferation and endoreplication (e.g. polyploidy and multi nucleation). Here, we developed a novel assay that combines automated live-cell microscopy and image processing algorithms to discriminate between proliferation and endoreplication by quantifying changes in the number of nuclei, changes in the number of cells, binucleation, and nuclear DNA content. We applied this assay to further prioritize hits from a primary screen for DNA synthesis, identifying 30 compounds that enhance proliferation of human induced pluripotent stem cell-derived cardiomyocytes. Among the most active compounds from the phenotypic screen are clinically approved L-type calcium channel blockers from multiple chemical classes whose activities were confirmed across different sources of human induced pluripotent stem cell-derived cardiomyocytes. Identification of compounds that stimulate human cardiomyocyte proliferation may provide new therapeutic strategies for heart failure.
机译:由于再生功能心脏组织的能力有限,美国超过500万人患有心力衰竭。一种潜在的治疗策略是提高常规心肌细胞的增殖。然而,通过常规标记物的有限能力区分心肌细胞增殖和本发明综合(例如多倍体和多核),对治疗剂的表型筛选受到挑战。在这里,我们开发了一种新的测定,其结合自动化的活细胞显微镜和图像处理算法,通过量化细胞核数量的变化,细胞数量,细胞的变化,细胞生物细胞和核DNA含量的变化来区分增殖和本发明的歧视。我们将该测定应用于来自初级筛选的进一步优先优先考虑DNA合成的,鉴定30种化合物,其增强人诱导的多能干细胞衍生的心肌细胞的增殖。来自表型筛选的最活跃的化合物中,临床批准的L型钙通道阻滞剂来自多种化学类,其在人类诱导的多能干细胞衍生的心肌细胞的不同来源中证实的活性。鉴定刺激人心肌细胞增殖的化合物可能为心力衰竭提供新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号